Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
about
Melanoma: tumor microenvironment and new treatments.USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein.Infiltrating lymphocytes and human papillomavirus-16--associated oropharyngeal cancer.Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.Profound impairment of adaptive immune responses by alkylating chemotherapyTumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?Variation of tumor-infiltrating lymphocytes in human cancers: controversy on clinical significance.Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy.Therapy-induced microenvironmental changes in cancer.FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration.Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionNew insights on the role of CD8(+)CD57(+) T-cells in cancer.Increased tumor-infiltrating CD8(+)Foxp3(+) T lymphocytes are associated with tumor progression in human gastric cancer.B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma.Terminally differentiated CD8+ T cells and CD57-FOXP3+CD8+ T cells are highly associated with the efficacy of immunotherapy using activated autologous lymphocytes.
P2860
Q33675676-72B8550B-B032-4C9A-B66F-57057E4B8701Q33755106-357C3802-EE80-44F8-BEFE-2BE7E4416BAEQ35053658-C0E9AC54-9E4D-41C7-B5BD-EECD0E81FF8DQ35913813-F8AD92BD-39BD-4CF4-9DDB-ECFDA390AF53Q35931423-024D9A6F-1AE6-43FF-8349-6C5834F68237Q36922577-36AD29BE-01D3-4D6A-82FE-189BAC228088Q37873379-9F6E0D8D-DBC1-4B87-A0F8-1202DB3D7B83Q37945304-709B0EBA-4CA8-4330-A797-34E57CDE9637Q38733052-A005ADC3-3BD2-4A87-AFB3-3854A681E10DQ38756772-8D4D93F5-36D7-4EBE-9777-E9E9D0D211C0Q39120137-6F3A4992-B42D-4920-A445-381985323E17Q41437712-565BBEB1-47A9-49F0-83F7-2879067DCFC1Q41474870-BEB3DE15-262F-46FA-8E4B-42945BCCFF74Q43916071-FF7C004D-3AA9-45CB-8431-81A49DFB2AFEQ44945891-8C4C4D6D-0666-42B5-B219-D6886A43F9E1Q54981146-F15E1CDA-4DDD-460D-A272-2016A05922F7
P2860
Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Tumor-reactive CD8+ early effe ...... imary and metastatic melanoma.
@en
Tumor-reactive CD8+ early effe ...... imary and metastatic melanoma.
@nl
type
label
Tumor-reactive CD8+ early effe ...... imary and metastatic melanoma.
@en
Tumor-reactive CD8+ early effe ...... imary and metastatic melanoma.
@nl
prefLabel
Tumor-reactive CD8+ early effe ...... imary and metastatic melanoma.
@en
Tumor-reactive CD8+ early effe ...... imary and metastatic melanoma.
@nl
P2093
P50
P1433
P1476
Tumor-reactive CD8+ early effe ...... rimary and metastatic melanoma
@en
P2093
Alessandra Molla
Claudia Vegetti
Fernando Ravagnani
Flavio Arienti
Hanspeter Pircher
Ilaria Bersani
Roberto Patuzzo
P304
P356
10.1158/0008-5472.CAN-10-2028
P407
P577
2010-09-21T00:00:00Z